This app has been exclusively created for participants in the medical study for GSK BE-conneCTD ILD 221672. It contains Televisit functionality and allows participants to complete questionnaires.

A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with interstitial lung disease (ILD) associated with connected tissue disease (CTD).